Senate committee advances bipartisan PBM, FDA reforms with eight related amendments
The Senate Health, Education, Labor and Pensions committee on Thursday advanced four new bills related to PBM and FDA reforms, as well as eight bipartisan amendments that would require pharma companies to disclose R&D costs, as well to remove gag clauses employed by PBMs, among other provisions.
On the overall PBM reform bill, lawmakers on both sides of the aisle largely agreed to provide for increased oversight of PBMs, including the banning of spread pricing — when a PBM charges payers for drugs more than they pay the pharmacy — and a requirement that PBMs pass through 100% of manufacturer rebates, discounts and fees.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
